Who are Dose D1 of interleukin-2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ontak, Ontak, Chrft5, Zenapax, Proleukin, Ontak.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dose-d1-of-interleukin-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dose D1 of interleukin-2 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose D1 of interleukin-2 (Dose D1 of interleukin-2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine. Area: Oncology.

phase 2 Cytokine Interleukin-2 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Dose D1 of interleukin-2 (Dose D1 of interleukin-2) — Assistance Publique - Hôpitaux de Paris. Interleukin-2 stimulates T-cell proliferation and activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dose D1 of interleukin-2 TARGET	Dose D1 of interleukin-2	Assistance Publique - Hôpitaux de Paris	phase 2	Cytokine	Interleukin-2 receptor
Ontak	E7777	Eisai	marketed	CD25-directed Cytotoxin	Interleukin-2 receptor	1999-01-01
Ontak	DENILEUKIN DIFTITOX	Eisai	marketed	CD25-directed Cytotoxin [EPC]	Interleukin-2 receptor	1999-01-01
Chrft5	BASILIXIMAB	Novartis	marketed	Interleukin-2 Receptor Blocking Antibody [EPC]	Interleukin-2 receptor subunit alpha	1998-01-01
Zenapax	DACLIZUMAB	Hoffman-La Roche	marketed	Interleukin-2 Receptor Blocking Antibody	Interleukin-2 receptor	1997-01-01
Proleukin	ALDESLEUKIN	Chiron	marketed	Lymphocyte Growth Factor [EPC]	Interleukin-2 receptor	1992-01-01
Ontak	Ontak	The University of Texas Health Science Center at San Antonio	marketed		Interleukin-2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine class)

Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Centre for Endocrinology and Reproductive Medicine, Italy · 1 drug in this class
Amgen · 1 drug in this class
Orasis Pharmaceuticals Ltd. · 1 drug in this class
Radboud University Medical Center · 1 drug in this class
Sandoz · 1 drug in this class
King's College London · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dose D1 of interleukin-2 — Competitive Intelligence Brief. https://druglandscape.com/ci/dose-d1-of-interleukin-2. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab